Precision BioSciences, Inc.
DTILNASDAQHealthcare● Active
$6.87
+$0.10(+1.48%)
Market Cap$88129418
P/E Ratio—
52W High$8.82
52W Low$3.53
Precision BioSciences, Inc. (DTIL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DTIL · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.34
Est. -$0.27 · -25.9%
Revenue
$0.01B
Est. $0.00B · +167.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
DTIL reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.60 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 5, 2026 | -$0.27 | -$0.34 | -25.9% | $0.01B | $0.00B | +167.6% |
| ▲ Q1 FY2026 | Mar 12, 2026 | -$0.21 | $0.36 | +271.4% | $0.03B | $0.01B | +276.9% |
| ▼ Q4 FY2025 | Nov 3, 2025 | -$0.31 | -$1.84 | -493.6% | $0.00B | $0.01B | -99.9% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.09 | -$2.13 | -2266.7% | $0.00B | $0.01B | -99.7% |
| ▼ Q2 FY2025 | May 15, 2025 | -$0.43 | -$2.21 | -413.9% | $0.00B | $0.01B | -99.5% |
| ▼ Q1 FY2025 | Mar 26, 2025 | -$2.09 | -$3.20 | -53.1% | $0.00B | $0.01B | -93.6% |
| ▼ Q4 FY2024 | Nov 4, 2024 | -$0.79 | -$2.83 | -258.2% | $0.00B | $0.00B | -86.5% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.60
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Miss
EPS Actual
-$0.34
EPS Est.
-$0.27
EPS Surpr.
-25.9%
Revenue
$0.01B
Q1 FY2026
Mar 12, 2026Beat
EPS Actual
$0.36
EPS Est.
-$0.21
EPS Surpr.
+271.4%
Revenue
$0.03B
Q4 FY2025
Nov 3, 2025Miss
EPS Actual
-$1.84
EPS Est.
-$0.31
EPS Surpr.
-493.6%
Revenue
$0.00B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$2.13
EPS Est.
-$0.09
EPS Surpr.
-2266.7%
Revenue
$0.00B
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$2.21
EPS Est.
-$0.43
EPS Surpr.
-413.9%
Revenue
$0.00B
Q1 FY2025
Mar 26, 2025Miss
EPS Actual
-$3.20
EPS Est.
-$2.09
EPS Surpr.
-53.1%
Revenue
$0.00B
Q4 FY2024
Nov 4, 2024Miss
EPS Actual
-$2.83
EPS Est.
-$0.79
EPS Surpr.
-258.2%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.03 | $0.03 | $0.03 | 1 |
| Q3 FY2027 | $-0.55 | $-0.55 | $-0.55 | 1 |
| Q2 FY2027 | $-0.54 | $-0.54 | $-0.54 | 1 |
| Q1 FY2027 | $-0.53 | $-0.53 | $-0.53 | 1 |
| Q4 FY2026 | $-0.46 | $-0.46 | $-0.46 | 1 |
| Q3 FY2026 | $-0.73 | $-0.73 | $-0.73 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 5, 2026 | -25.9% | $7.63 | $7.45 | -2.36% |
| ▲ Q1 FY2026 | Mar 12, 2026 | +271.4% | $5.06 | $5.67 | +12.06% |
| ▼ Q4 FY2025 | Nov 3, 2025 | -493.6% | $8.16 | $7.36 | -9.80% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -2266.7% | $4.81 | $4.57 | -4.99% |
| ▼ Q2 FY2025 | May 15, 2025 | -413.9% | $4.95 | $4.55 | -8.08% |
| ▼ Q1 FY2025 | Mar 26, 2025 | -53.1% | $5.09 | $4.53 | -11.00% |
| ▼ Q4 FY2024 | Nov 4, 2024 | -258.2% | $9.02 | $8.29 | -8.09% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +549.4% | $9.53 | $9.57 | +0.42% |
Q2 FY2026-2.36%
Report Date
May 5, 2026
EPS Beat/Miss
-25.9%
Price Before
$7.63
Price After
$7.45
Q1 FY2026+12.06%
Report Date
Mar 12, 2026
EPS Beat/Miss
+271.4%
Price Before
$5.06
Price After
$5.67
Q4 FY2025-9.80%
Report Date
Nov 3, 2025
EPS Beat/Miss
-493.6%
Price Before
$8.16
Price After
$7.36
Q3 FY2025-4.99%
Report Date
Aug 7, 2025
EPS Beat/Miss
-2266.7%
Price Before
$4.81
Price After
$4.57
Q2 FY2025-8.08%
Report Date
May 15, 2025
EPS Beat/Miss
-413.9%
Price Before
$4.95
Price After
$4.55
Q1 FY2025-11.00%
Report Date
Mar 26, 2025
EPS Beat/Miss
-53.1%
Price Before
$5.09
Price After
$4.53
Q4 FY2024-8.09%
Report Date
Nov 4, 2024
EPS Beat/Miss
-258.2%
Price Before
$9.02
Price After
$8.29
Q3 FY2024+0.42%
Report Date
Aug 1, 2024
EPS Beat/Miss
+549.4%
Price Before
$9.53
Price After
$9.57
Avg Beat Reaction+6.24%
Avg Miss Reaction-7.39%
Beat Rate2 / 8 quarters
Largest Move+12.06% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DTIL ends December
Precision BioSciences, Inc. (DTIL) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.34 — missing the analyst consensus of $-0.27 by -25.9%. The next DTIL earnings date is expected around September 1, 2026.
Each quarter, investors track DTIL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DTIL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DTIL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DTIL earnings · 5 questionsPrecision BioSciences, Inc.'s next earnings report is expected around September 1, 2026. DTIL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DTIL historically reports after market close (AMC).
DTIL earnings datewhen is DTIL earningsDTIL next earnings datewhen does DTIL report earningsDTIL earnings calendar
▸ Source: FMP · Precision BioSciences, Inc. SEC filings · US GAAP · Precision BioSciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026